What Dologesic (ANALGESICSOPIOID) Treats: Main Uses and Benefits

The fixed-dose combination of acetaminophen and tramadol is used to address significant discomfort, particularly when additional management of discomfort is required after using non-opioid options. It is applied in clinical settings that involve acute or unstable symptom patterns, assisting with conditions characterized by periods of heightened symptoms. This combination is generally used in areas where short-term symptom management is appropriate for symptoms that create noticeable physiological strain.

Its therapeutic relevance includes symptomatic support for musculoskeletal pain, discomfort linked to Osteoarthritis, and specific forms of neuropathic pain such as diabetic neuropathy and Fibromyalgia. It is also commonly used for short-term management following procedures like minor surgery or dental work. This approach helps manage symptom clusters that interfere with daily comfort and contributes to improved comfort during periods of increased distress.

“It supports patients during difficult episodes by easing distress and helps improve day-to-day comfort during symptomatic periods.”

---

Quick Fact

Quick Fact: Symptomatic Support for Intense Discomfort and Post-Procedural Symptoms.

Regulatory References

1. DailyMed full prescribing information

Who Can and Cannot Use Dologesic (Acetaminophen/Tramadol)?

Official regulatory information defines specific population eligibility based on age, organ function, and existing conditions. The medicine is primarily approved for adults and adolescents 12 years and older.

---

Absolute Contraindications

Use of this combination medicine is strictly contraindicated (prohibited) in several patient populations, including:

• Children younger than 12 years of age.
• Adolescents younger than 18 years for post-operative pain after tonsillectomy or adenoidectomy.
• Patients with severe hepatic impairment or significant respiratory depression.
• Patients who have used Monoamine Oxidase Inhibitors (MAOIs) within the last 14 days.
• Individuals with known hypersensitivity to either active ingredient or any opioid.

---

Population Restrictions and Limitations

Population Group	Regulatory Status
Severe Renal Impairment	Not recommended for patients with Creatinine Clearance less than 10 ml/min.
Moderate Renal Impairment	Use requires the dosing interval to be prolonged (e.g., 12-hourly intervals).
Elderly Patients (Over 75)	Use requires a minimum dosing interval of 6 hours due to potentially prolonged elimination.
Pregnancy and Lactation	Not recommended; prolonged use in pregnancy carries the risk of Neonatal Opioid Withdrawal Syndrome (NOWS).

Use also requires close monitoring and caution in patients with a recognized risk for seizures or those with chronic pulmonary disease.

Interactions with other medicines and products

Documented Interaction Domains

The interaction profile for Dologesic is primarily structured by drug combinations that pose an additive risk of central nervous system (CNS) depression and those that increase the risk of hepatotoxicity due to the acetaminophen component.

Significant Interaction Constraints

Interacting Product Category	Restriction / Clinical Concern
Other Acetaminophen-Containing Products	Do not use. Severe liver damage risk is increased if the maximum daily amount is exceeded.
Alcohol (Ethanol)	Avoid. Increases the risk of severe liver damage (hepatotoxicity), particularly with chronic excessive consumption.
CNS Depressants (e.g., sedatives, tranquilizers, other opioids, muscle relaxants)	Avoid or use with caution. Increases effects such as severe drowsiness, respiratory depression, and impaired mental status.
Anticholinergic Agents (e.g., some antihistamines, psychiatric medicines)	May increase the risk of anticholinergic side effects (e.g., confusion, dry mouth).
Warfarin	May result in a clinically significant interaction affecting coagulation; monitoring may be necessary.

Regulatory Summary

Official regulatory documents require that patients do not take this product if they are taking sedatives or tranquilizers without consulting a healthcare professional. The strongest regulatory warning is against the co-administration of any other product containing acetaminophen due to the documented major interaction risk of additive hepatotoxicity. These constraints define the product's safety requirements for co-administration.

Multimodal Targeting of Central Pain Receptors

The drug's mechanism involves two distinct pathways that modulate nociceptive signaling within the Central Nervous System ( CNS). The Tramadol component's active metabolite ( M1) directly acts as an agonist on the mu-opioid receptor (mu OR), while the Acetaminophen component reduces the synthesis of prostaglandins that mediate central nociception (via COX inhibition) and modulates the Endocannabinoid System (via CB1 and TRPV1 receptors). This combination of non-overlapping mechanisms alters the functional processing of nociceptive signals.

---

Enhancement of Spinal Inhibitory Pathways

A distinct part of the mechanism involves the Tramadol parent drug and its enantiomers acting as reuptake inhibitors of Serotonin and Norepinephrine in the spinal cord. This action increases the concentration of these neurotransmitters, enhancing the descending inhibitory pathways that dampen the transmission of nociceptive signals. This physiological dampening complements the central receptor activation, leading to a multimodal interruption of signal transmission.

---

️ Mechanism Limitations and Metabolic Dependence

The functional output of the mu OR agonism is constrained by the body's CYP2D6 metabolic enzyme, which is required to convert Tramadol into the active M1 metabolite. Individuals with low CYP2D6 activity exhibit a mechanistically weaker opioid response. Additionally, Acetaminophen's action is constrained in the presence of intense peripheral inflammation due to biochemical interference at the COX enzyme site.

How to Use Dologesic (Tramadol/Acetaminophen)

This section details the administration and dosing instructions for the fixed-dose combination of Tramadol and Acetaminophen. The medicine is strictly for oral use as a solid, film-coated tablet.

Standard Dosing and Frequency

The typical initial dose for adults is 2 tablets of the 37.5 mg Tramadol / 325 mg Acetaminophen combination. Subsequent doses are taken as needed for relief, with a required interval of at least 4 to 6 hours between administrations. The total daily intake must not exceed 8 tablets in a 24-hour period, which constitutes the maximum recommended daily dose for this formulation. The tablets may be administered with or without food.

Physical Administration and Duration

To ensure proper release of the ingredients, the tablet must be swallowed whole using liquid and must not be broken, crushed, or chewed. This combination product is generally specified for short-term use only, such as a course lasting five days or less. If a dose is missed, it is advised to take the next dose at the regularly scheduled time and not taking a double dose to compensate.

Population-Specific Adjustments

Specific adjustments to the dosing schedule are applied for certain patient groups. For older adults (over 75 years of age), the dosing interval must be extended to not less than six hours. For individuals with severe kidney impairment (Creatinine Clearance < 30 mL/min), the maximum permitted dose is 2 tablets every 12 hours. The medicine is not recommended for patients with impaired hepatic function and is contraindicated in children younger than 12 years of age.

Research Evidence / Overview of Studies

---

A. Core Clinical Trials Summary

The research landscape for this medication primarily consists of randomized controlled trials (RCTs) and meta-analyses that focused on its use for managing chronic pain associated with musculoskeletal conditions.

Studies have explored the drug's activity in laboratory models. Research has investigated whether the drug is associated with changes in mobility, particularly in study participants with moderate-to-severe limitations. The primary outcome measures reported in the included trials focused on pain intensity scores, as measured by standardized scales. Additionally, studies have evaluated the time course and duration of changes in chronic pain symptoms, assessing findings related to symptom control.

---

B. Pharmacovigilance and Safety Profile

Safety data primarily come from Phase III clinical trials and subsequent post-market surveillance studies. Researchers reported on the range of adverse events observed during the course of these investigations.

Research has also examined the drug's profile in specific populations:

• Elderly Participants: Studies exploring the drug's profile in older adults included assessments of drug disposition.
• Renal Impairment: Trials frequently excluded individuals with severe kidney impairment. For those with mild-to-moderate impairment, researchers assessed the findings regarding drug exposure.
• Hepatic Health: Studies noted that individuals with pre-existing liver conditions were often excluded or assessed separately in trials.

---

C. Combination Therapy and Other Factors

Research has compared outcomes between combination therapy (the drug plus a non-pharmacological intervention) and monotherapy (the drug alone). The available data have focused on comparing the impact on reported quality of life metrics and daily function scores between these two groups.

Research reports have often emphasized the role of other factors alongside the drug's investigation. For example, some studies explored whether the drug's effect was different in participants who also maintained a specific physical activity regimen.

---

D. Proposed Mechanism of Action

Research included assessments of physiological markers in study participants, and other studies explored the drug's influence on specific physiological processes. The full, detailed mechanism by which the drug may exert its observed effects is still the subject of ongoing investigation. This medication is one option studied for individuals with the targeted chronic conditions.

Key Studies & References

1. Opioid Dosage and Equivalency: Safety Considerations in Renal and Hepatic Impairment

Common questions about Dologesic (ANALGESICSOPIOID) (FAQ)

Q: How long will it take for Dologesic to start working?

Studies and official information indicate that the active ingredients work relatively quickly. For the Tramadol component, the time when the maximum concentration is reached (peak effect) is generally observed between 2 and 3 hours after taking the tablet. The onset of pain relief can potentially begin within the first hour.

Q: Can Dologesic be used for long-term chronic pain management?

Regulatory information advises that this medicine should not be administered for longer than is strictly necessary. If repeated use or long-term treatment is necessary, regulatory documents advise that careful, regular monitoring should be performed to assess the continued need for the medicine.

Q: What kind of pain is Dologesic best for?

The official product information indicates that Dologesic is approved for the symptomatic treatment of moderate to severe pain. The medicine is indicated for use in patients whose pain requires a combination of both a non-opioid and an opioid analgesic component for effective relief.

Q: What should I do if I start experiencing symptoms of Serotonin Syndrome while taking Dologesic?

Serotonin Syndrome is listed in regulatory documents as a serious, potentially life-threatening risk associated with this medicine. Symptoms can include agitation, rapid heartbeat, uncoordinated movements, and confusion. If serious signs such as these are noticed, official guidelines advise seeking prompt medical attention.

How to Store and Dispose of Dologesic (ANALGESICSOPIOID)?

Official guidelines for Dologesic ( Acetaminophen/ Tramadol Hydrochloride) focus on maintaining product stability and ensuring security, as mandated for a controlled substance.

---

Storage Requirements

Storage Temperature: The tablets must be stored at Controlled Room Temperature, ideally between 20 C and 25 C. Temperatures between 15 C and 30 C are acceptable for brief periods. The medicine must be kept in a tightly closed container.

Child Safety: It is mandatory to keep Dologesic out of the sight and reach of children due to the serious risk of accidental opioid overdose.

---

Official Disposal Instructions

Unused or expired Dologesic must be disposed of according to regulations for opioid analgesics. The preferred method is using an authorized drug take-back program. If a take-back option is not immediately available, the FDA advises flushing the tablets down the toilet to prevent accidental ingestion and diversion. Disposal must comply with all state and local laws.